Securian Asset Management Inc. Sells 292 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Securian Asset Management Inc. decreased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 2.7% during the 4th quarter, HoldingsChannel reports. The fund owned 10,622 shares of the medical device company’s stock after selling 292 shares during the quarter. Securian Asset Management Inc.’s holdings in Cooper Companies were worth $976,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Cooper Companies during the 4th quarter worth approximately $691,000. Highland Capital Management LLC bought a new stake in shares of Cooper Companies during the 4th quarter worth approximately $4,004,000. Caprock Group LLC bought a new stake in shares of Cooper Companies during the 4th quarter worth approximately $282,000. Franklin Resources Inc. raised its stake in shares of Cooper Companies by 194.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after purchasing an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Cooper Companies by 6.6% during the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after purchasing an additional 14,687 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Performance

COO opened at $81.22 on Friday. The firm has a market cap of $16.24 billion, a P/E ratio of 41.65, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 52-week low of $77.05 and a 52-week high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The business’s fifty day moving average is $91.20 and its 200-day moving average is $98.90.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Analysts Set New Price Targets

COO has been the topic of a number of analyst reports. JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus dropped their price target on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Wells Fargo & Company increased their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Robert W. Baird dropped their price target on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Finally, StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average target price of $111.89.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.